Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15224107 | 0.89 | CYP2D6 (0.58) | CYP2D6EPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL8290227 | 0.84 | GLA (0.57) | CYP2D6EPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL11863514 | 0.84 | EPHX1 (0.52) | CYP2D6EPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL13519 | 0.82 | FAAH (0.57) | CYP2D6EPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL10702291 | 0.81 | CYP2D6 (0.61) | CYP2D6EPHX1SMN1; SMN2CA12CA1 | |
| SCHEMBL21096969 | 0.81 | HDAC3 (0.52) | CYP2D6EPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL8051690 | 0.81 | HDAC3 (0.52) | CYP2D6EPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL19227335 | 0.81 | HDAC3 (0.52) | CYP2D6EPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL27405108 | 0.81 | FAAH (0.60) | EPHX1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30259898 | 0.80 | FAAH (0.59) | EPHX1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572398-B2 | GLP-1 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2023-02-07 | — | — | US | disclosed |
| US-20170320927-A1 | GLP-1 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-11-09 | — | — | US | disclosed |
| US-8822452-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2014-09-02 | — | — | US | disclosed |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | CYP2D6 395/4885EPHX1 227/4885HDAC3 1439/4885 |
| US-11572398-B2 | GLP-1 derivatives and uses thereof | GLP1R, GIPR, GCG | CYP2D6 2531/4885EPHX1 2107/4885HDAC3 2643/4885 |
| US-20170320927-A1 | GLP-1 Derivatives and Uses Thereof | GLP1R, GIPR, GCG | CYP2D6 2531/4885EPHX1 2107/4885HDAC3 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.